{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T23:08:03Z","timestamp":1765235283763,"version":"3.46.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"S6","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["MMW Fortschr Med"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s15006-025-5490-6","type":"journal-article","created":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T23:03:24Z","timestamp":1765235004000},"page":"3-8","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prospektives CKD-Screening bei Risikopatienten in der Hausarztpraxis","Prospective CKD screening of high-risk patients in general practice"],"prefix":"10.1007","volume":"167","author":[{"given":"J\u00fcrgen","family":"Flohr","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Kemerle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastian","family":"Klein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ralph","family":"Wendt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,9]]},"reference":[{"key":"5490_CR3194","doi-asserted-by":"crossref","unstructured":"Torra R. Kidney health matters: a global imperative for public health. Nephrol Dial Transplant. 2024;39(9):1371\u20134","DOI":"10.1093\/ndt\/gfae083"},{"key":"5490_CR3198","doi-asserted-by":"crossref","unstructured":"Sanchez-Ni\u00f1o MD et al. Clinical proteomics in kidney disease as an exponential technology: heading towards the disruptive phase. Clin Kidney J. 2017;10(2):188\u201391","DOI":"10.1093\/ckj\/sfx023"},{"key":"5490_CR3202","doi-asserted-by":"crossref","unstructured":"Wanner C et al. InspeCKD \u2013 Analyse zur Nutzung von Labordiagnostik im Kontext der chronischen Nierenerkrankung. MMW Fortschr Med. 2024;166(Suppl 4):9\u201317","DOI":"10.1007\/s15006-024-3684-y"},{"key":"5490_CR3206","doi-asserted-by":"crossref","unstructured":"Time to sound the alarm about the hidden epidemic of kidney disease. Nature. 2024;628(8006):7\u20138","DOI":"10.1038\/d41586-024-00961-5"},{"key":"5490_CR3210","doi-asserted-by":"crossref","unstructured":"Foreman KJ et al. Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016 \u2013 40 for 195 countries and territories. Lancet. 2018;392(10159):2052-2090","DOI":"10.1016\/S0140-6736(18)31694-5"},{"key":"5490_CR3214","unstructured":"Girndt M et al. The prevalence of renal failure. Results from the German Health Interview and Examination Survey for Adults, 2008\u20132011 (DEGS1). Dtsch Arztebl Int. 2016;113(6):85-91"},{"key":"5490_CR3218","doi-asserted-by":"crossref","unstructured":"Szczech LA et al. Primary care detection of chronic kidney disease in adults with type-2 diabetes: the ADD-CKD Study (awareness, detection and drug therapy in type 2 diabetes and chronic kidney disease). PLoS ONE. 2014;9(11):e110535","DOI":"10.1371\/journal.pone.0110535"},{"key":"5490_CR3068","unstructured":"Leipziger Gesundheitsnetz. Behandlungspfade. 2025. https:\/\/www.gesundheitsnetz-leipzig.de\/behandlungspfade\/ (aufgerufen am 5. Juni 2025)"},{"key":"5490_CR3224","doi-asserted-by":"crossref","unstructured":"Levey AS et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604","DOI":"10.7326\/0003-4819-150-9-200905050-00006"},{"key":"5490_CR3228","doi-asserted-by":"crossref","unstructured":"Tangri N et al. A predictive model for progression of chronic kidney disease to kidney failure. JAMA. 2011;305(15):1553\u20139","DOI":"10.1001\/jama.2011.451"},{"key":"5490_CR3232","unstructured":"DEGAM, Deutsche Gesellschaft f\u00fcr Nephrologie. Risikokalkulator Nierenversagen: Risiko Nierenversagen. 2025. https:\/\/www.risiko-nierenversagen.de\/risikokalkulator-nierenversagen (aufgerufen am 5. Juni 2025)"},{"key":"5490_CR3238","doi-asserted-by":"crossref","unstructured":"Van Mil D et al. Participation rate and yield of two home-based screening methods to detect increased albuminuria in the general population in the Netherlands (THOMAS): a prospective, randomised, open-label implementation study. Lancet. 2023;402(10407):1052\u201364","DOI":"10.1016\/S0140-6736(23)00876-0"},{"key":"5490_CR3242","doi-asserted-by":"crossref","unstructured":"Vart P et al. Estimated lifetime benefit of combined RAAS and SGLT2 inhibitor therapy in patients with albuminuric CKD without diabetes. Clin J Am Soc Nephrol. 2022;17(12):CJN.08900722","DOI":"10.2215\/CJN.08900722"},{"key":"5490_CR3246","doi-asserted-by":"crossref","unstructured":"Neuen BL et al. Estimated lifetime cardiovascular, kidney, and mortality benefits of combination treatment with SGLT2 inhibitors, GLP-1 receptor agonists, and nonsteroidal MRA compared with conventional care in patients with type 2 diabetes and albuminuria. Circulation. 2024;149(6):450\u201342","DOI":"10.1161\/CIRCULATIONAHA.123.067584"},{"key":"5490_CR3250","doi-asserted-by":"crossref","unstructured":"Levin A et al. Executive summary of the KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease: known knowns and known unknowns. Kidney Int. 2024;105(4):684\u2013701","DOI":"10.1016\/j.kint.2023.10.016"},{"key":"5490_CR3254","doi-asserted-by":"crossref","unstructured":"Wiviott SD et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2018;380(4):347\u201357; doi:10.1056\/nejmoa1812389","DOI":"10.1056\/NEJMoa1812389"},{"key":"5490_CR3258","doi-asserted-by":"crossref","unstructured":"Mosenzon O et al. Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE\u2013TIMI 58 randomised trial. Lancet Diabetes Endocrinol. 2019;7(8):606\u201317","DOI":"10.1016\/S2213-8587(19)30180-9"},{"key":"5490_CR3268","doi-asserted-by":"crossref","unstructured":"Aboukaoud M et al. Sodium-glucose co-transporter 2 inhibitors and severe urinary tract infections: real-world meta-analysis of cohort studies. Ann Pharmacoth er. 2025;59(10):891\u2013903","DOI":"10.1177\/10600280241312432"},{"key":"5490_CR3272","doi-asserted-by":"crossref","unstructured":"Ferro CJ et al. ABCDE to identify and prevent chronic kidney disease: a call to action. Nephrol Dial Transplant. 2025;40(9):1786\u201398","DOI":"10.1093\/ndt\/gfaf057"}],"container-title":["MMW - Fortschritte der Medizin"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15006-025-5490-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s15006-025-5490-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15006-025-5490-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T23:03:34Z","timestamp":1765235014000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.springermedizin.de\/doi\/10.1007\/s15006-025-5490-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":19,"journal-issue":{"issue":"S6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["5490"],"URL":"https:\/\/doi.org\/10.1007\/s15006-025-5490-6","relation":{},"ISSN":["1438-3276","1613-3560"],"issn-type":[{"value":"1438-3276","type":"print"},{"value":"1613-3560","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"9 December 2025","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J\u00fcrgen Flohr und Ralph Wendt erhielten Honorare f\u00fcr Vortrags- und\/oder Beratungst\u00e4tigkeit f\u00fcr Astra Zeneca, Santis, Boehringer Ingelheim, Bayer und Lilly.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}